Immunome (NASDAQ:IMNM) Sees Strong Trading Volume

Immunome, Inc. (NASDAQ:IMNM) saw an uptick in trading volume on Thursday . 662,051 shares traded hands during trading, a decline of 14% from the previous session’s volume of 769,601 shares.The stock last traded at $15.99 and had previously closed at $15.50.

Wall Street Analyst Weigh In

IMNM has been the topic of a number of research analyst reports. Piper Sandler decreased their target price on Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Wedbush restated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research report on Tuesday, August 13th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $29.00.

Immunome Trading Down 2.0 %

The business has a fifty day moving average price of $14.51 and a 200-day moving average price of $16.24. The stock has a market capitalization of $898.94 million, a PE ratio of -1.99 and a beta of 1.77.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). Immunome had a negative return on equity of 38.19% and a negative net margin of 2,435.02%. The business had revenue of $2.36 million for the quarter, compared to analysts’ expectations of $2.62 million. On average, equities analysts anticipate that Immunome, Inc. will post -1.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Immunome

In related news, CFO Max Rosett sold 14,380 shares of the stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the sale, the chief financial officer now directly owns 47,476 shares in the company, valued at approximately $760,090.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Jack Higgins sold 3,524 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the sale, the insider now directly owns 16,000 shares in the company, valued at $222,880. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $16.01, for a total value of $230,223.80. Following the transaction, the chief financial officer now owns 47,476 shares in the company, valued at approximately $760,090.76. The disclosure for this sale can be found here. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Large investors have recently made changes to their positions in the business. Jump Financial LLC bought a new position in Immunome in the 4th quarter worth $172,000. Mayo Clinic bought a new stake in Immunome during the 4th quarter valued at approximately $1,161,000. Avidity Partners Management LP purchased a new position in shares of Immunome during the 4th quarter worth approximately $14,268,000. Clear Creek Financial Management LLC bought a new position in shares of Immunome in the 1st quarter worth approximately $547,000. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Immunome in the 1st quarter valued at approximately $1,044,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.